Product
CCX140-B
5 clinical trials
5 indications
Indication
focal segmental glomerulosclerosisIndication
Type 2 Diabetes MellitusIndication
Diabetic NephropathyIndication
Focal Segmental GlomerulosclerosisIndication
Kidney DiseaseClinical trial
An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic SyndromeStatus: Terminated, Estimated PCD: 2020-06-24
Clinical trial
A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes MellitusStatus: Completed, Estimated PCD: 2010-10-01
Clinical trial
A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Effect of CCX140-B on Albuminuria in Subjects With Type 2 Diabetes MellitusStatus: Completed, Estimated PCD: 2013-02-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX140-B in Diabetic NephropathyStatus: Completed, Estimated PCD: 2014-08-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)Status: Completed, Estimated PCD: 2020-02-19